An interventional study of Neurofeedback in Rheumatoid Arthritis and Chronic Widespread Pain, sponsored by NHS Greater Glasgow and Clyde. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by NHS Greater Glasgow and Clyde · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 314 studies in Arthritis, Rheumatoid with a site in United Kingdom — 18 open to participants now, 40 under way, 3 of them phase 3. Arthritis, Rheumatoid · United Kingdom.
Among the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom, this one is the 217th largest by planned enrollment of the 239 interventional ones that give a count, is one of 2 that started in 2024, is one of 26 with no phase, reaches primary completion later than 16 of the 39 other live ones, and was the 302nd registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →18 of the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Ulster · Sites in United Kingdom
Ages 18+
Quell Therapeutics Limited · Sites in United Kingdom, Germany, Spain
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18–75
AstraZeneca · Sites in United Kingdom, United States, Argentina and 14 more countries
Ages 18+
Hoffmann-La Roche · Sites in United Kingdom, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
314 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 69 · Phase 3 81 · Phase 4 37
First in 1995; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 210 across the 239 interventional studies, 151 across the 75 observational. Of the 257 that completed or were terminated, 137 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
244 of 314 have an industry lead sponsor. The 10 most frequent:
NHS Greater Glasgow and Clyde is the lead sponsor of 220 studies on the registry; 38 are open to participants now.
NHS Greater Glasgow and Clyde has 7 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
9 of the studies in Arthritis, Rheumatoid with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT06240299NHS Greater Glasgow and ClydeNeurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR) | 2027-01-29 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 314 studies in Arthritis, Rheumatoid with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.
Study Schedule For each participant, the intervention paradigm consists of a 1-week diary of pain, sleep and fatigue prior to baseline assessment, 10 intervention sessions 2-3 times per week, post-intervention assessment and remote post-intervention follow-up interview, one month after the last intervention. Hence, each participant will be enrolled in the study for 11-13 weeks, including the follow-up assessment. In case of short-term health problems (e.g., Covid 19, flu, seasonal allergy, etc), experimental sessions can be postponed for up to one week. A maximum of two sessions can be missed otherwise participants will be withdrawn from the study.
Intervention EEG will be recorded with one unit (16 channels) of a modular EEG device (usbamp, Gtec, Austria) requiring 5-10 min setup. Before neurofeedback training (NF), daily baseline EEG activity will be recorded for 2 min, during which participants will sit in a relaxed state, with eyes open. After that, participants will see a graphical user interface (GUI) consisting of three bars that correspond to signal power in three frequency bands: theta, alpha and beta. The bars change colour and height proportionally to the band power. Participants will be aiming to decrease theta and beta and to increase alpha band power as compared to the baseline values. If the power of a particular band passes the threshold level set by the daily baseline recording, the corresponding column turns green, otherwise, the colour is red. NF will be provided from the sensorimotor cortex (electrode locations C4/C3). In total, each training session lasts for 30 min. A second, 2min long EEG recording in the relaxed state with eyes opened will be recorded immediately after the NF session. The experimenter will advise participants on successful mental strategies in the first 3 sessions and will let participants choose their preferred strategy during sessions 4-10.
Baseline EEG recording Participants will be comfortably sitting approximately 1 meter from a computer screen. EEG will be recorded with 4 units (64 channels, passive electrodes) of modular multichannel EEG. This setup requires up to 30 min. EEG will be recorded for 8 min in alternative 2 min blocks of relaxed eyes open and eyes closed state. During eyes open recording, they will be asked to look at a cross in the centre of the screen to avoid excessive eye movements. Following this, participants will be asked to perform cue-based motor imagination practice, i.e., to imagine moving their left and right hands and feet every time they see a cue on a computer screen. Cues will appear in semi-random order, each cue appearing 60 times. A total of 180 trials will be split in six sub-sessions, each totalling 30 trials (10 right hand, 10 left hand, 10 feet).
Quantitative Sensory Testing Quantitative Sensory Testing (QST) is a standardised methodology to study pain sensitivity in humans. A QST protocol includes a series of noxious and non-noxious stimuli delivered to a patient, followed by a semi-objective method for the patient to rate their perception of each stimulus. In this study, participants will complete an abbreviated QST battery to characterise pain sensitivity. All participants who consent to this procedure will undergo familiarisation training prior to data collection to reduce QST-related anxiety. QST comprise of pressure pain sensitivity test and cuff algometry test. Pressure pain sensitivity (15-20 minutes) will be assessed using a digital algometer with a 1 cm2 rubber probe to quantify pressure pain thresholds (PPT) at multiple body sites. Pressure will be manually increased up to 1000 kilo Pascals (kPa). Cuff algometry (10 minutes) will be used to measure deep muscle tonic pain. This consists of a computer controlled air compressor which delivers varying degrees of pressure to a Velcro-adjusted cuff applied to one gastrocnemius muscle.
Visit 1 (week 0): Screening, Consent, Baseline EEG , Questionnaires and Research assessments (including QST). The total duration of Visit 1 will be 4-5 hours including comfort breaks and time for EEG setup.
Visits 2-11 (weeks 1-5): Neurofeedback sessions 1-10, Pain questionnaires (structured and semi-structured). The study visit, including EEG setup (time to put it on and off), intervention and debriefing will take 60-70 min.
Visit 12 (week 6): post-intervention EEG, Questionnaires and Research assessments (including QST). This assessment will take place within 7 (±5) days after the last NF session. The total duration of Visit 12 will be 4-5 hours including comfort breaks and time for EEG setup.
Visit 13 (week 10): remote follow-up. A 10 min semi-structured interview, covering topics such as pain, sleep, fatigue and any adverse effects. The interview will take place over the phone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: visual neurofeedback Research Assessments * EEG: relaxed state and motor imagery * Quantitative sensory testing Questionnaires (after each intervention session): * visual analog scale - rate pain intensity * pain description and pain intensity reporting * mental strategies, affects (emotional experience) and sensations during NF * adverse event reporting * NASA task load index Questionnaires (week before and week after intervention weeks) * Routine Assessment of Patient Index Data 3 (RAPID3) * American College of Rheumatology Fibromyalgia Scale (ACRFS) * McGill Pain Questionnaire * Patient-Reported Outcomes Measurement Information System (PROMIS) Depression * PROMIS-Anxiety * PROMIS-Fatigue * PROMIS-Sleep related impairment * Pain Number Rating Scale * Generalised Self-Efficiency Scale questionnaire * Multidimensional Health Locus of Control Scale questionnaires Remote follow-up: semi-structured interview over the telephone
Procedure: Neurofeedback
A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen
Difference in nociplastic pain (Visual Analog Scale)
Difference in nociplastic pain following 10 sessions of neurofeedback, compared to baseline, as measured by a on a 10 point Visual Analog Scale (VAN), from 1 to 10, where 10 is the highest possible pain. Improvement is indicated by a reduction in score.
Time frame: 4 weeks
Difference in nociplastic pain (ACRFS)
Difference in nociplastic pain following 10 sessions of neurofeedback, compared to baseline, as measured by the American College of Rheumatology Fibromyalgia Scale (ACRFS). The score ranges between 0-19, with improvement indicated by a reduction in score.
Time frame: 5 weeks
Difference in nociplastic pain (ACRFS) 1 month post-intervention
Difference in nociplastic pain 1 month after the last session, compared to baseline, as measured by the American College of Rheumatology Fibromyalgia Scale (ACRFS). The score ranges between 0-19, with improvement indicated by a reduction in score.
Time frame: 10 weeks
Success of performing neurofeedback
EEG power in theta (4-8 Hz), alpha (8-12 Hz) , low beta (13-20 Hz), high beta (20-30) and gamma (30-45 Hz) during NF compared to daily baseline, to assess the success of performing neurofeedback
Time frame: 5 weeks
Mental strategies during neurofeedback
Self-reported mental strategies (a goal-directed mental action performed in order to control the graphical user interface) and affects (emotional experience e.g.happy, excited, frustrated, anxious etc.) during NF
Time frame: 5 weeks
Multidimensional Health Locus of Control Scale
Questionnaire that evaluates the quality of life in patients with diseases or disabilities, containing 18 questions or statements. For each statement, the participant rates their level of agreement on a 6 point scale, from strongly disagree, to strongly agree.
Time frame: 6 weeks
NASA task load index
Questionnaire that rates perceived workload in order to assess the neurofeedback task. The participant rates, on a 20-point visual scale, each of the following aspects: mental demand, physical demand, temporal demand, performance, effort and frustration. Higher scores represent a higher task workload.
Time frame: 5 weeks
7-Day Symptom Diary
Pain severity following 10 NF sessions (as measured by 7-Day Symptom Diary (Number Rating Scale between 0-10). A reduction in score represents better outcome.
Time frame: 5 weeks
McGill Pain Questionnaire
Multidimensional pain questionnaire. Different types of pain are rated from 0-3 (none to severe pain). A reduction in score represents better outcome.
Time frame: 6 weeks
Self-report of adverse events
Adverse events self-report after each NF session
Time frame: 5 weeks
Plan to share: Yes — Shared on request
Supporting information: Study protocol
Time frame: After study end
Access criteria: Data will be shared upon reasonable request
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jan 2027, 31 months after the start.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 31 months is above that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NHS Greater Glasgow and Clyde →